Skip to content
Search

Latest Stories

NHS to expand medical drone delivery network with Zipline and Apian

NHS to expand medical drone delivery network with Zipline and Apian

Northumbria Healthcare NHS Foundation Trust will launch the new service by the autumn of 2024.  

Global instant logistics leader, Zipline is partnering with UK drone delivery startup, Apian Aero to launch a drone delivery programme of critical medical supplies for the Northumbria Healthcare NHS Foundation Trust.


The new service, expected to begin in the autumn of 2024, will see delivery of medical supplies to hospitals, GPs and care homes, using electric, autonomous drones.

Zipline announced the partnership on Sunday, and said drone delivery service will help provide timely access to prescription medicines, wound care products, joint replacement implants, and other frequently ordered medical products, which could allow healthcare providers to reduce the number of cancelled procedures, and thus decrease wait times.

Also, the expansion of the programme will help in creating local job opportunities in the region, it added.

James Mackey, CEO of Northumbria Healthcare NHS Foundation Trust said: “This expansion with Zipline and Apian is an exciting next step as we strive to improve services for the hundreds of thousands of patients we serve. We believe this innovative technology could be used to improve healthcare outcomes, save money and eliminate supply chain complexities, and we're keen to get started."

The aim is to serve more than 30 GP, care and health facilities across the region, including Hexham General Hospital, Wansbeck General Hospital, Haltwhistle War Memorial Hospital, with plans to expand the operations over time.

Dr. Christopher Law, Medical Director and Co-Founder of Apian, commented: “I’ve seen first-hand the impact that running out of supplies can have on patient health outcomes.

“Healthcare should benefit from on-demand delivery, much like consumers now do in their personal lives. Delivering critical products with drones, where and when they’re most needed, will improve supply chain efficiency and give doctors, nurses and clinicians more time to focus on the most important thing — their patients.”

Apian has built a platform that integrates both healthcare and aviation, creating a fully automated, on-demand delivery system, which allows the NHS to easily place orders and Zipline to seamlessly fulfill them.

Keller Rinaudo Cliffton, CEO and Co-Founder of Zipline, said: “Today 3,000-pound gas vehicles driven by humans are used to deliver three-pound packages billions of times per year. It’s expensive, slow and bad for the environment.

“This decision means that the NHS can start to transition delivery to solutions that are ten times as fast, less expensive, and zero emission. This service will be delivered at a fraction of the cost of the existing solution, and will help drive financial savings to the NHS in the longer term."

Apian and Northumbria Healthcare completed a successful Stage 1 of drone trials between February and May 2023.

Zipline will build a hub for its operations near the Northumbria Specialist Emergency Care Hospital in Cramlington, Northumberland.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less